PCOD vs PCOS: There Is Only One Diagnosis

No. They refer to the same condition. PCOS — polycystic ovary syndrome — is the term used in clinical guidelines and research. PCOD, polycystic ovarian disease, is an older colloquial name that persists in everyday use, particularly in India.

The clearest evidence for this is what the guidelines contain. The 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, published across Human Reproduction, JCEM and the European Journal of Endocrinology, does not use the term PCOD anywhere.

• There is one diagnosis, defined by the Rotterdam criteria.
• PCOD is not a milder form, an early stage, or a subtype.
• No guideline body defines PCOD separately.
• The distinction commonly described online has no diagnostic basis.

This matters more than a naming quibble. Being told you have 'only PCOD, not PCOS' implies a less serious condition requiring less follow-up, and that implication is not supported by any diagnostic framework.

By the Rotterdam criteria, which require two of three features to be present. That requirement is why presentations vary so widely, and why two people with the same diagnosis can look quite different.

• Irregular or absent ovulation.
• Clinical or biochemical signs of excess androgens.
• Polycystic ovarian morphology on ultrasound, or elevated AMH in adults.

The 2023 guideline made one change worth knowing about. Serum AMH could be used for defining polycystic ovarian morphology in adults, as an alternative to ultrasound rather than in addition to it.

The guideline is explicit that they are alternatives: either serum AMH or ultrasound may be used, but both tests should not be performed, to limit overdiagnosis. It also states that serum AMH should not yet be used in adolescents.

• Can PCOS Be Cured Naturally? What Actually Changes the Outcome
• Ozempic and Fertility: What to Know Before Trying to Conceive
• What Is Diminished Ovarian Reserve? What the Tests Do and Do Not Tell You (2026)
• Can Stress Cause Infertility? What the Evidence Actually Shows
• IUI vs IVF — Which Treatment Is Right for You? (2026)
• Endometriosis and IVF: What the Evidence Says About Surgery First
• Fertility Tests for Women: What Each One Checks, and When

Not always, and this is the point most often missed. Where two criteria are already met, the third adds nothing to the diagnosis — it only adds cost and, sometimes, alarm at seeing the word 'cysts' on a report.

The 2023 guideline states it plainly: in patients with irregular menstrual cycles and hyperandrogenism, an ovarian ultrasound is not necessary for PCOS diagnosis.

The follicles seen on such a scan are also not cysts in the usual sense. They are ordinary immature follicles, present in larger numbers, which is what the 'polycystic' in the name describes and why the name is widely considered a poor one.

Our fuller article on PCOS and its effect on fertility covers what the diagnosis means for conceiving, and AMH explained covers the marker now offered as an alternative to the scan.

Letrozole, where the difficulty is ovulation. The 2023 international guideline recommends that letrozole should be considered as first-line medical therapy for ovulation induction in women with PCOS seeking pregnancy, which reversed a long-settled order of treatment.

Clomiphene citrate held that position for decades and is still widely prescribed. It remains a reasonable option; it is no longer the preferred first step.

• The usual obstacle in PCOS is ovulation, not egg supply.
• Ovulation induction sits several rungs below IVF on the treatment ladder.
• IVF is not the starting point for most people with PCOS.
• A high AMH in PCOS reflects follicle numbers, not better egg quality.

Because ovulation is the obstacle, treatment usually begins by restoring it rather than bypassing it — which is why being offered IVF as a first step for PCOS warrants a question about what was tried before it.

Two specific harms follow from treating PCOD as a separate, gentler condition, and both are avoidable with clearer language. One affects how closely you are followed up afterwards, and the other affects how much testing you are asked to pay for.

• Reassurance that reduces follow-up for a condition with metabolic implications.
• Confusion about which guideline applies, since none covers PCOD.
• Unnecessary ultrasound where two criteria are already met.
• Both AMH and ultrasound performed, which the guideline advises against.

If you have been given one label rather than the other, the useful question is not which you have. It is which of the three Rotterdam features you meet, and what your clinician plans to monitor as a result.